Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model

Peer Review reports

Original Submission
23 May 2018	Submitted	Original manuscript
6 Aug 2018	Reviewed	Reviewer Report - Berenice Gitomer
17 Aug 2018	Reviewed	Reviewer Report - Reviewer 2
6 Nov 2018	Author responded	Author comments - Hayley Bennett Wilton
Resubmission - Version 2
6 Nov 2018	Submitted	Manuscript version 2
14 Nov 2018	Reviewed	Reviewer Report - Berenice Gitomer
19 Feb 2019	Author responded	Author comments - Hayley Bennett Wilton
Resubmission - Version 3
19 Feb 2019	Submitted	Manuscript version 3
Publishing
11 Mar 2019	Editorially accepted
23 Apr 2019	Article published	10.1186/s12882-019-1290-5

Back to article page